[go: up one dir, main page]

MX2017008844A - Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. - Google Patents

Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.

Info

Publication number
MX2017008844A
MX2017008844A MX2017008844A MX2017008844A MX2017008844A MX 2017008844 A MX2017008844 A MX 2017008844A MX 2017008844 A MX2017008844 A MX 2017008844A MX 2017008844 A MX2017008844 A MX 2017008844A MX 2017008844 A MX2017008844 A MX 2017008844A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
alcoholic fatty
treatment
combination therapy
Prior art date
Application number
MX2017008844A
Other languages
English (en)
Inventor
C Harriman Geraldine
Kapeller-Libermann Rosana
F Westlin William
James Harwood H
Original Assignee
Gilead Apollo Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Apollo Llc filed Critical Gilead Apollo Llc
Publication of MX2017008844A publication Critical patent/MX2017008844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee métodos para tratar, estabilizar o aminorar la gravedad o avance de una enfermedad de hígado graso no alcohólico utilizando un inhibidor de ACC solo o con uno o más agentes terapéuticos adicionales.
MX2017008844A 2015-01-09 2016-01-08 Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. MX2017008844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
MX2017008844A true MX2017008844A (es) 2018-03-14

Family

ID=56356482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008844A MX2017008844A (es) 2015-01-09 2016-01-08 Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.

Country Status (13)

Country Link
US (2) US20180021341A1 (es)
EP (2) EP3242722A4 (es)
JP (2) JP2018501276A (es)
KR (1) KR20170102299A (es)
CN (1) CN107106873A (es)
AU (1) AU2016205138A1 (es)
BR (1) BR112017014341A2 (es)
CA (1) CA2972919A1 (es)
EA (2) EA201791258A1 (es)
HK (2) HK1246232A1 (es)
MX (1) MX2017008844A (es)
SG (1) SG11201705361PA (es)
WO (1) WO2016112305A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN107922390B (zh) 2015-07-06 2019-05-10 吉利德科学公司 Cot调节剂及其使用方法
ES2939833T3 (es) * 2015-11-25 2023-04-27 Gilead Apollo Llc Inhibidores de ACC de pirazol y usos de los mismos
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2018085623A1 (en) 2016-11-04 2018-05-11 Children's Hospital Medical Center Compositions and methods of treating liver disease
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
EP3538159B1 (en) * 2016-11-10 2023-04-05 Galmed Research and Development Ltd. Inhibition of fibrosis in non-alcoholic fatty liver disease patients
IL309558A (en) * 2016-11-10 2024-02-01 Galmed Res And Development Ltd Fibrosis treatment
CN110062764B (zh) 2016-12-05 2024-07-02 儿童医院医学中心 结肠类器官及其制备和使用方法
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US10759812B2 (en) 2017-01-22 2020-09-01 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
WO2018171699A1 (zh) * 2017-03-24 2018-09-27 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
EP3600310A1 (en) * 2017-03-28 2020-02-05 Gilead Sciences, Inc. Methods of treating liver disease
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
US20180333401A1 (en) * 2017-04-12 2018-11-22 Gilead Sciences, Inc. Methods of treating liver disease
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
KR102699958B1 (ko) * 2017-04-18 2024-08-29 장피트 엘라피브라노르와 같은 ppar 작용제 및 아세틸-coa 카르복실라아제 (acc) 저해제를 포함하는 조합
US11583570B2 (en) * 2017-04-24 2023-02-21 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
WO2018236896A1 (en) * 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR THE TREATMENT OF NAFLD AND NASH
CN111201234A (zh) * 2017-07-17 2020-05-26 南京瑞捷医药科技有限公司 新型化合物及其作为acc抑制剂的用途
US11186587B2 (en) * 2017-07-26 2021-11-30 Nanjing Sanhome Pharmaceutical Co., Ltd. Compound as ACC inhibitor and use thereof
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
EP3676262A4 (en) 2017-09-03 2021-03-31 Angion Biomedica Corp. VINYLHETEROCYCLENE AS RHO-ASSOCIATED COILED COIL KINASE (ROCK) INHIBITORS
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
AU2018345817B2 (en) * 2017-10-06 2021-10-28 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
WO2019085772A1 (zh) * 2017-11-06 2019-05-09 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
HRP20241555T1 (hr) 2018-01-31 2025-01-17 Heparegenix Gmbh Inhibitori protein kinaze mkk4 za poticanje regeneracije jetre ili smanjenje ili sprječavanje smrti hepatocita
JP2021520394A (ja) * 2018-04-17 2021-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、処置方法及びその使用
AU2019257632A1 (en) * 2018-04-24 2020-11-26 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3823968A1 (en) 2018-07-16 2021-05-26 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20210322324A1 (en) * 2018-08-14 2021-10-21 Avolynt Method for treating primary sclerosing cholangitis
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
EP3846821B1 (en) * 2018-09-06 2023-10-04 Galmed Research and Development Ltd. Combination therapy for the treatment of liver disease
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
JP2022513101A (ja) * 2018-11-20 2022-02-07 中国医▲薬▼研究▲開▼▲発▼中心有限公司 スピロ環系化合物及びその医薬用途
SG11202107434PA (en) 2019-01-15 2021-08-30 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
JP7631217B2 (ja) * 2019-04-10 2025-02-18 ジェンフィット 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
WO2021000242A1 (zh) * 2019-07-02 2021-01-07 广东东阳光药业有限公司 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
US20220340561A1 (en) 2019-07-29 2022-10-27 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
KR20210027169A (ko) * 2019-08-30 2021-03-10 (주)셀트리온 비알콜성 지방간염(NASH, Nonalcoholic Steatohepatitis) 치료 또는 예방을 위한 약학 조성물
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
EP4098261A4 (en) * 2020-03-11 2024-02-28 Dong-A ST Co., Ltd. PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS
CN115397511A (zh) 2020-03-30 2022-11-25 吉利德科学公司 Cot抑制剂化合物(s)-6-(((1-(双环[1.1.1]戊-1-基)-1h-1,2,3-三唑-4-基)2-甲基-1-氧代-1,2-二氢异喹啉-5-基)甲基)))氨基8-氯-(新戊基氨基)喹啉-3-甲腈的固体形式
CN115397824B (zh) 2020-04-02 2024-10-22 吉利德科学公司 用于制备cot抑制剂化合物的方法
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20230210822A1 (en) * 2020-05-21 2023-07-06 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
EP4000616A1 (en) * 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
JP7705475B2 (ja) 2021-03-29 2025-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｈｋ阻害剤
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
US20250006331A1 (en) * 2021-08-31 2025-01-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
WO2024263785A1 (en) * 2023-06-20 2024-12-26 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009259839A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
ES2665580T3 (es) * 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
BR112015028214A2 (pt) * 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
CN105358152A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
HK1221660A1 (zh) 2013-05-10 2017-06-09 Gilead Apollo, Llc Acc抑制劑和其用途
JP6434498B2 (ja) * 2013-05-10 2018-12-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用

Also Published As

Publication number Publication date
KR20170102299A (ko) 2017-09-08
EA201892625A1 (ru) 2019-07-31
US20180021341A1 (en) 2018-01-25
JP2020109130A (ja) 2020-07-16
HK1243369A1 (zh) 2018-07-13
EP3242722A1 (en) 2017-11-15
AU2016205138A1 (en) 2017-07-13
WO2016112305A1 (en) 2016-07-14
CA2972919A1 (en) 2016-07-14
CN107106873A (zh) 2017-08-29
EP3597271A1 (en) 2020-01-22
SG11201705361PA (en) 2017-08-30
BR112017014341A2 (pt) 2018-03-27
EA201791258A1 (ru) 2017-12-29
US20190381045A1 (en) 2019-12-19
JP2018501276A (ja) 2018-01-18
EP3242722A4 (en) 2018-07-11
HK1246232A1 (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
IL254719A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
EA201790998A1 (ru) Иммуннорегуляторные агенты
GB2541571A (en) Pharmaceutical compositions
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201591509A1 (ru) Ингибиторы cdc7
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX376201B (es) Compuestos inhibidores de metaloenzima.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201792227A1 (ru) Лечение рака легких ингибиторами глутаминазы
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
PH12017501879A1 (en) Methods for treating cancer
MX2021006326A (es) Inhibidores de pcna.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX390320B (es) Farmaco de combinacion.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين